EGFR and colorectal cancer: Dianthin-panitumumab and dianthin-cetuximab immunotoxins engineered from the full length therapeutic IgG conjugated to recombinant dianthin similarly showed no killing of EGFR-overexpressing colorectal cancer cells when administered at concentrations below 10 nM [67].